The Administrative Core (Core A) will function as a central coordinating unit of this PO1 Program and its main charge will be to develop and execute the collaborative initiatives among different components and integrate the programmatic activities, manage the administrative, financial and compliance matters, and communicate with the scientific advisory and regulatory authorities. Dr. Xue-Ru Wu, the Principal Investigator of this PO1 Program, with the assistance of a part-time Program Coordinator, Ms. Jessica O'Halloran, will manage the daily operation of this Core. The small operating budget will allow Dr. Wu to manage, in a highly efficient and cost-effective manner, the scientific, budgetary and administrative matters of this PO1 Program.
The Specific Aims of the Core are to: ensure the sustained thematic focus of this PO1; launch, coordinate and implement the collaborative initiatives; integrate the scientific activities and resources; assess the overall conduct and progress of the entire program and each component Project and Core; apply for and renew protocols for animal, biosafety and recombinant DNA studies; communicate with the institutional Sponsored Program Administration (SPA) and National Cancer Institute; report to and seek advice from the Advisory Committee; organize monthly Project Directors' meetings, seminars and research conferences; and prioritize program resources and resolve potential conflicts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA165980-06A1
Application #
9785819
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
New York University
Department
Type
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Jin, Honglei; Sun, Wenrui; Zhang, Yuanmei et al. (2018) MicroRNA-411 Downregulation Enhances Tumor Growth by Upregulating MLLT11 Expression in Human Bladder Cancer. Mol Ther Nucleic Acids 11:312-322
Hua, Xiaohui; Xu, Jiheng; Deng, Xu et al. (2018) New compound ChlA-F induces autophagy-dependent anti-cancer effect via upregulating Sestrin-2 in human bladder cancer. Cancer Lett 436:38-51
Peng, Minggang; Wang, Jingjing; Zhang, Dongyun et al. (2018) PHLPP2 stabilization by p27 mediates its inhibition of bladder cancer invasion by promoting autophagic degradation of MMP2 protein. Oncogene :
Li, Xin; Tian, Zhongxian; Jin, Honglei et al. (2018) Decreased c-Myc mRNA Stability via the MicroRNA 141-3p/AUF1 Axis Is Crucial for p63? Inhibition of Cyclin D1 Gene Transcription and Bladder Cancer Cell Tumorigenicity. Mol Cell Biol 38:
Guo, Xirui; Huang, Haishan; Jin, Honglei et al. (2018) ISO, via Upregulating MiR-137 Transcription, Inhibits GSK3?-HSP70-MMP-2 Axis, Resulting in Attenuating Urothelial Cancer Invasion. Mol Ther Nucleic Acids 12:337-349
Weng, Mao-Wen; Lee, Hyun-Wook; Park, Sung-Hyun et al. (2018) Aldehydes are the predominant forces inducing DNA damage and inhibiting DNA repair in tobacco smoke carcinogenesis. Proc Natl Acad Sci U S A 115:E6152-E6161
Yu, Yonghui; Jin, Honglei; Xu, Jiheng et al. (2018) XIAP overexpression promotes bladder cancer invasion in vitro and lung metastasis in vivo via enhancing nucleolin-mediated Rho-GDI? mRNA stability. Int J Cancer 142:2040-2055
Lee, Hyun-Wook; Park, Sung-Hyun; Weng, Mao-Wen et al. (2018) E-cigarette smoke damages DNA and reduces repair activity in mouse lung, heart, and bladder as well as in human lung and bladder cells. Proc Natl Acad Sci U S A 115:E1560-E1569
Zhu, Junlan; Li, Yang; Tian, Zhongxian et al. (2017) ATG7 Overexpression Is Crucial for Tumorigenic Growth of Bladder Cancer In Vitro and In Vivo by Targeting the ETS2/miRNA196b/FOXO1/p27 Axis. Mol Ther Nucleic Acids 7:299-313
Weng, Mao-Wen; Lee, Hyun-Wook; Choi, Bongkun et al. (2017) AFB1 hepatocarcinogenesis is via lipid peroxidation that inhibits DNA repair, sensitizes mutation susceptibility and induces aldehyde-DNA adducts at p53 mutational hotspot codon 249. Oncotarget 8:18213-18226

Showing the most recent 10 out of 65 publications